Targets › ADORA2B
32 programs from 32 companies in 50 trials: 22 Phase 2, 13 Phase 4, 8 Phase 1, 7 Phase 3; Other, Cardiovascular, Oncology; next expected readout Dec 2026.
Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. (UniProt, P29275)
Open in Phaseline: the race on ADORA2B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| St Joseph University, Beirut, Lebanon | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 4 | Lumbar Radiculopathy | Dec 2026 |
| Region Skane | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Chronic Coronary Syndrome | Dec 2026 |
| National Institute of Cardiovascular Diseases, Pakistan | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | ST-Segment Elevation Myocardial Infarction (STEMI) | Dec 2026 |
| University of Alabama at Birmingham | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Premature Infant Disease | May 2027 |
| Anne E. Zepeski | adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Supraventricular Tachycardia (SVT) | Jul 2027 |
| Semmelweis University | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Apnea of Prematurity | Dec 2027 |
| Weill Medical College of Cornell University | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Premature Ventricular Contraction (PVC) | Dec 2027 |
| VA Office of Research and Development | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 4 | Diabetic Kidney Disease | Jan 2028 |
| Vastra Gotaland Region | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Takotsubo Syndrome | Dec 2028 |
| RDC Clinical | Caffeine Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Exercise; Migraine; Healthy; Vibration Therapy … | – |
| Al-Azhar University | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Chronic Kidney Diseases | Dec 2026 |
| Tanta University | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | IBS - Irritable Bowel Syndrome; Rheumatoid Arthritis | May 2027 |
| NICHD Global Network for Women's and Children's Health | Caffeine Citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 3 | Hypoxic Ischemic Encephalopathy (HIE) | Dec 2029 |
| Rashid Latif Medical College | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 3 | Supraventricular Tachycardia (SVtach) | – |
| University of Washington | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Medication-related Osteonecrosis of the Jaw | – |
| Beni-Suef University | pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Embryo Transfer | – |
| New York Medical College | Defibrotide Adenosine A2 receptor agonist; Plasminogen activator; Adenosine A1 receptor agonist | ADORA2B, ADORA2A, PLG, ADORA1, F2 | Phase 2 | Sickle Cell Disease; Sinusoidal Obstruction Syndrome | Dec 2026 |
| Mostafa Bahaa | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Epilepsy | Dec 2026 |
| Ihab Elsayed Hassan | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Inflammatory Bowel Diseases | Jan 2027 |
| University Hospital, Limoges | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Medication-related Osteonecrosis of the Jaw (MRONJ) | Apr 2027 |
| Ministry of Health, Saudi Arabia | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 2 | Prematurity | Oct 2027 |
| University of Rochester | Caffeine Citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 2 | Neonatal Apnea | Jul 2028 |
| M.D. Anderson Cancer Center | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Lymphedema; Fibrosis Syndrome | May 2029 |
| Gilead Sciences | Etrumadenant Adenosine A2a receptor antagonist; Adenosine A2b receptor antagonist | ADORA2A, ADORA2B | Phase 2 | Lung Cancer; Oligometastatic Prostate Cancer; Rectal Cancer; Pancreatic Ductal Adenocarcinoma … | Sep 2029 |
| University of Wisconsin, Madison | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 2 | Kidney Injury | Mar 2030 |
| University Health Network, Toronto | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Non-Small Cell Lung Cancer | Nov 2031 |
| Dwight Owen | PBF-1129 Adenosine A2B receptor antagonist | ADORA2B | Phase 1 | Metastatic Lung Non-Small Cell Carcinoma | Dec 2026 |
| Indiana University | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 1 | Preterm Labor With Preterm Delivery | Jun 2027 |
| University of Chicago | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 1 | Enhanced Recovery After Surgery in a Pediatric Population | Dec 2027 |
| University of North Carolina, Chapel Hill | Caffeine Citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 1 | Hypoxic-Ischemic Encephalopathy | Jul 2028 |
| McMaster University | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 1 | Chronic Cough (CC) | – |
| Nishtar Medical University | Caffeine Citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 1 | Apnea of Prematurity | – |
Apnea of Prematurity (3) Hypoxic-Ischemic Encephalopathy (2) Supraventricular Tachycardia (SVT) (1) Medication-related Osteonecrosis of the Jaw (1) Medication-related Osteonecrosis of the Jaw (MRONJ) (1) Premature Infant Disease (1) Sickle Cell Disease (1) Sinusoidal Obstruction Syndrome (1) Lung Cancer (1) Oligometastatic Prostate Cancer (1) Rectal Cancer (1) Pancreatic Ductal Adenocarcinoma (1)
small molecule (28), mixed (2), protein or peptide (1)
Anne E. Zepeski (1) University of Washington (1) University Hospital, Limoges (1) Semmelweis University (1) University of Alabama at Birmingham (1) New York Medical College (1) Gilead Sciences (1) RDC Clinical (1) Mostafa Bahaa (1) M.D. Anderson Cancer Center (1) Weill Medical College of Cornell University (1) Vastra Gotaland Region (1) University of Chicago (1) Dwight Owen (1) McMaster University (1) VA Office of Research and Development (1) Region Skane (1) Ihab Elsayed Hassan (1) Indiana University (1) Ministry of Health, Saudi Arabia (1)
ADORA2A (31) ADORA1 (19) ADORA3 (18) PDE5A (11) PDE4A (11) PDE3A (11) PLG (1) F2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.